RUBICON vs SYMBIOTEC: Stock Comparison
RUBICON RESEARCH is the larger company by market capitalisation. RUBICON RESEARCH shows a higher dividend yield, faster revenue growth and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
RUBICON leads 4; SYMBIOTEC leads 0 of 4
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | RUBICON | SYMBIOTEC |
|---|---|---|
| Sector | Healthcare | — |
| Industry | Pharmaceuticals | — |
Price
| Metric | RUBICON | SYMBIOTEC |
|---|---|---|
| Live Price | ₹1,791.2 | ₹1,038.6 |
| Day Change | 1.39% | -0.4% |
| Volume | 1.17 L | 2.75 L |
| 52-Week High | ₹1,899 | ₹1,193.7 |
| 52-Week Low | ₹570.75 | ₹934.2 |
| Distance from 52W High | -5.68% | -12.99% |
Valuation
| Metric | RUBICON | SYMBIOTEC |
|---|---|---|
| Market Cap | ₹29,632 Cr | ₹6,624 Cr |
| P/E Ratio | 102.12x | — |
| P/B Ratio | 22.84x | — |
| EPS | ₹4.99 | — |
| Book Value | ₹77.93 | — |
| Dividend Yield | 0.08% | 0% |
Growth
| Metric | RUBICON | SYMBIOTEC |
|---|---|---|
| Revenue Growth (TTM YoY) | 43.5% | 0% |
| EPS Growth (TTM YoY) | 96.6% | 0% |
| Qtr Sales Growth | -19.95% | — |
| Qtr Profit Growth | -2.75% | — |
Profitability & Leverage
| Metric | RUBICON | SYMBIOTEC |
|---|---|---|
| ROE | 19.14% | — |
| ROCE | 20.49% | — |
| Net Margin | 13.48% | 0% |
| Operating Margin | 20.68% | — |
| Debt to Equity | 0.2x | — |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | RUBICON | SYMBIOTEC |
|---|---|---|
| Promoter Holding | 23.93%▼ 0.04 pp | 33.28% |
| FII Holding | 7.52%▼ 0.02 pp | 21.08% |
| DII Holding | 9.43%▼ 0.59 pp | 27.52% |
| Public Holding | 23.3%▲ 0.72 pp | 18.12% |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: RUBICON RESEARCH and SYMBIOTEC PHARMALAB.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.